Roundup: GSK Acquires Trispecific T Cell-Engager from Chimagen, Sanofi & Cheplapharm Form Strategic Partnership

GlaxoSmithKline (GSK) terminated its Phase 2 trial for Alzheimer's drug GSK4527226, co-developed with Alector Inc. The study, which aimed to assess the drug's efficacy and safety, was terminated rather than completed. This development may impact investor expectations for GSK's neurology pipeline and its partner Alector Inc.

Sanofi announced a $925 million flu vaccine facility in Toronto, with partial funding from the federal government ($55 million) and the City of Toronto. The project is expected to create 300 jobs and enhance local vaccine supply. Premier Doug Ford emphasized Ontario's investment philosophy and the importance of domestic vaccine production.

Sanofi (SNY) agreed to transfer 20 mature drugs and three plants to Cheplapharm, receiving a 26.4% stake. The deal, set for 2027, allows Sanofi to focus on innovation while maintaining 2026 financial guidance. Employee arrangements at the affected sites will remain unchanged.

Sanofi (SNY) will transfer 20 mature drugs and 3 plants to Cheplapharm in exchange for a 26.4% stake, aiming to complete the deal by Q3 2027. The transaction is not expected to impact Sanofi's 2026 financial guidance.

Cheplapharm, advised by Latham & Watkins, will acquire 20 medicines and three manufacturing sites from Sanofi. Sanofi will gain a 26.4% stake in Cheplapharm, with the deal expected to close in Q3 2027. Cheplapharm anticipates becoming the fifth-largest German pharma company upon completion.

GSK agreed to acquire a trispecific T cell-engager from Chimagen Biosciences for up to $750M. The asset targets multiple myeloma, with phase I trials expected in 2027. GSK aims to improve tolerability and efficacy. Latham & Watkins advised on the deal.